RU2019115428A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019115428A3 RU2019115428A3 RU2019115428A RU2019115428A RU2019115428A3 RU 2019115428 A3 RU2019115428 A3 RU 2019115428A3 RU 2019115428 A RU2019115428 A RU 2019115428A RU 2019115428 A RU2019115428 A RU 2019115428A RU 2019115428 A3 RU2019115428 A3 RU 2019115428A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427903P | 2016-11-30 | 2016-11-30 | |
| US62/427,903 | 2016-11-30 | ||
| US201762479609P | 2017-03-31 | 2017-03-31 | |
| US62/479,609 | 2017-03-31 | ||
| PCT/US2017/063918 WO2018102536A1 (en) | 2016-11-30 | 2017-11-30 | Methods for treatment of cancer comprising tigit-binding agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019115428A RU2019115428A (ru) | 2021-01-11 |
| RU2019115428A3 true RU2019115428A3 (enExample) | 2021-04-02 |
| RU2765410C2 RU2765410C2 (ru) | 2022-01-28 |
Family
ID=62241934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019115428A RU2765410C2 (ru) | 2016-11-30 | 2017-11-30 | Способы лечения рака, включающие связывающие tigit агенты |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11230596B2 (enExample) |
| EP (1) | EP3548071A4 (enExample) |
| JP (2) | JP7126269B2 (enExample) |
| KR (1) | KR102461228B1 (enExample) |
| CN (1) | CN110662552A (enExample) |
| AU (1) | AU2017368155B2 (enExample) |
| BR (1) | BR112019010943A8 (enExample) |
| CA (1) | CA3044664C (enExample) |
| IL (1) | IL266847B2 (enExample) |
| MX (1) | MX2019006072A (enExample) |
| NZ (1) | NZ753515A (enExample) |
| RU (1) | RU2765410C2 (enExample) |
| WO (1) | WO2018102536A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3605088A1 (en) | 2008-04-09 | 2020-02-05 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| NZ753515A (en) * | 2016-11-30 | 2022-02-25 | Oncomed Pharm Inc | Methods for treatment of cancer comprising tigit-binding agents |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| CN108948182A (zh) * | 2018-07-25 | 2018-12-07 | 中国人民解放军第四军医大学 | Tigit-ecd重组蛋白抗同种异体免疫排斥反应的应用 |
| TWI728400B (zh) * | 2018-07-26 | 2021-05-21 | 美商美國禮來大藥廠 | Cd226促效劑抗體 |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| KR20220012296A (ko) | 2019-05-20 | 2022-02-03 | 싸이튠 파마 | 암 또는 감염성 질환 치료를 위한 IL-2/IL-15Rβγ 작용제 투여 요법 |
| AU2020290916A1 (en) * | 2019-06-13 | 2021-11-04 | Green Cross Corporation | Antibody to TIGIT and use thereof |
| US11667709B2 (en) | 2019-09-24 | 2023-06-06 | Industrial Technology Research Institute | Anti-TIGIT antibodies and methods of use |
| US20220340660A1 (en) * | 2019-10-01 | 2022-10-27 | Merck Sharp & Dohme Corp. | Biomarkers for anti-tigit antibody treatment |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| CN115943312A (zh) | 2020-05-07 | 2023-04-07 | 法国居里学院 | 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途 |
| BR112022025801A2 (pt) | 2020-06-18 | 2023-10-03 | Hoffmann La Roche | Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| JP2023550685A (ja) | 2020-10-26 | 2023-12-05 | サイチューン ファーマ | 扁平上皮癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト |
| WO2022090202A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022120187A2 (en) * | 2020-12-03 | 2022-06-09 | Shattuck Labs, Inc. | Method of determining resistance to checkpoint inhibitor therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| KR20240024241A (ko) | 2021-06-23 | 2024-02-23 | 싸이튠 파마 | 인터루킨 15 변이체 |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| EP4384204A1 (en) | 2021-08-13 | 2024-06-19 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| WO2023234743A1 (ko) * | 2022-06-03 | 2023-12-07 | (주)지아이이노베이션 | 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도 |
| AU2023284422A1 (en) | 2022-06-07 | 2024-12-19 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7282570B2 (en) | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20080050809A1 (en) | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| WO2003068943A2 (en) | 2002-02-13 | 2003-08-21 | Incyte Corporation | Secreted proteins |
| JP2005535290A (ja) | 2002-02-22 | 2005-11-24 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| EP1537878B1 (en) | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| US20040121370A1 (en) | 2002-09-11 | 2004-06-24 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| US7550800B2 (en) | 2003-06-06 | 2009-06-23 | Chih-Hsin Wang | Method and apparatus transporting charges in semiconductor device and semiconductor memory device |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| WO2006124667A2 (en) | 2005-05-12 | 2006-11-23 | Zymogenetics, Inc. | Compositions and methods for modulating immune responses |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| JPWO2007043635A1 (ja) | 2005-10-07 | 2009-04-16 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
| WO2007053648A2 (en) | 2005-10-31 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| BRPI0717024A2 (pt) | 2006-10-06 | 2014-03-11 | Takeda Pharmaceutical | Anticorpo, célula de hibridoma, agente de diagnótico, medicamento, métodos para prevenir/tratar câncer, para induzir apoptose células cancerosas , para inibir crescimento de células cancerosas e para destruir células cancerosas, uso de um anicorpo monoclonal e agente para prevenir ou tratar câncer de mama. |
| DE102008028564A1 (de) | 2007-07-03 | 2009-01-08 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Hydrauliksystem zum Erzeugen eines Vorsteuerdruckes zum Ansteuern einer Getriebekomponente |
| PL4365189T3 (pl) | 2007-07-09 | 2025-05-26 | F. Hoffmann-La Roche Ag | Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów |
| EP3605088A1 (en) | 2008-04-09 | 2020-02-05 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| AU2011215685B2 (en) | 2010-02-12 | 2015-08-20 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| JP6066732B2 (ja) | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| TW201238976A (en) | 2011-02-23 | 2012-10-01 | Hoffmann La Roche | Antibodies against human IL33R and uses thereof |
| BR122022000334B1 (pt) | 2011-08-01 | 2023-03-21 | Genentech, Inc | Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| AR093788A1 (es) | 2012-12-04 | 2015-06-24 | Oncomed Pharm Inc | Inmunoterapia con agentes de enlace |
| CN103073644B (zh) | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| US9062104B2 (en) | 2013-03-14 | 2015-06-23 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| PT2992017T (pt) | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Anticorpos dirigidos contra a morte programada 1 (pd-1) |
| RU2702108C2 (ru) | 2013-07-16 | 2019-10-04 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CN114081946A (zh) | 2014-03-12 | 2022-02-25 | 耶达研究与开发有限公司 | 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤 |
| EP3119913B1 (en) | 2014-03-21 | 2021-01-06 | The Brigham and Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| MX2016017288A (es) | 2014-07-16 | 2017-06-27 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| US20160355589A1 (en) | 2014-08-19 | 2016-12-08 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
| WO2016073282A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| WO2016109546A2 (en) | 2014-12-30 | 2016-07-07 | Genentech, Inc. | Methods and compositions for prognosis and treatment of cancers |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| JP6976241B2 (ja) | 2015-08-14 | 2021-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗ｔｉｇｉｔ抗体 |
| JP6861418B2 (ja) | 2015-09-02 | 2021-04-28 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体 |
| US20180251548A1 (en) | 2015-09-14 | 2018-09-06 | Compass Therapeutics Llc | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta |
| MY186016A (en) | 2015-09-25 | 2021-06-14 | Genentech Inc | Anti-tigit antibodies and methods of use |
| SG10201912736UA (en) | 2015-10-01 | 2020-02-27 | Potenza Therapeutics Inc | Anti-tigit antigen-binding proteins and methods of use thereof |
| IL261188B (en) | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| US10731128B2 (en) * | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| NZ753515A (en) * | 2016-11-30 | 2022-02-25 | Oncomed Pharm Inc | Methods for treatment of cancer comprising tigit-binding agents |
| SG11201907278VA (en) | 2017-02-28 | 2019-09-27 | Seattle Genetics Inc | Anti-tigit antibodies |
| WO2018187191A1 (en) * | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| BR112019025035A2 (pt) * | 2017-06-01 | 2020-06-30 | Compugen Ltd. | método para tratar câncer |
| WO2018223002A1 (en) * | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd 123 cd3 |
| GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019023504A1 (en) | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | ANTI-TIGIT ANTIBODIES |
| JP2021502330A (ja) * | 2017-10-20 | 2021-01-28 | フレッド ハッチンソン キャンサー リサーチ センター | Ｔｉｇｉｔおよび／またはｃｄ１１２ｒを標的とするか、またはｃｄ２２６過剰発現を含む、組成物および免疫治療の方法 |
| IL310398A (en) * | 2018-04-18 | 2024-03-01 | Xencor Inc | Proteins from heterodimeric il-15/il-15rα fc and their uses |
| AT521173B1 (de) | 2018-06-27 | 2019-11-15 | Trumpf Maschinen Austria Gmbh & Co Kg | Biegewerkzeug mit Distanzelement |
-
2017
- 2017-11-30 NZ NZ753515A patent/NZ753515A/en not_active IP Right Cessation
- 2017-11-30 WO PCT/US2017/063918 patent/WO2018102536A1/en not_active Ceased
- 2017-11-30 RU RU2019115428A patent/RU2765410C2/ru active
- 2017-11-30 AU AU2017368155A patent/AU2017368155B2/en active Active
- 2017-11-30 CA CA3044664A patent/CA3044664C/en active Active
- 2017-11-30 MX MX2019006072A patent/MX2019006072A/es unknown
- 2017-11-30 US US16/464,820 patent/US11230596B2/en active Active
- 2017-11-30 BR BR112019010943A patent/BR112019010943A8/pt unknown
- 2017-11-30 KR KR1020197017345A patent/KR102461228B1/ko active Active
- 2017-11-30 CN CN201780074119.5A patent/CN110662552A/zh active Pending
- 2017-11-30 EP EP17876358.7A patent/EP3548071A4/en not_active Withdrawn
- 2017-11-30 JP JP2019529206A patent/JP7126269B2/ja active Active
-
2019
- 2019-05-23 IL IL266847A patent/IL266847B2/en unknown
-
2020
- 2020-12-11 US US17/119,883 patent/US11136384B2/en active Active
-
2021
- 2021-12-09 US US17/547,178 patent/US20220340653A1/en not_active Abandoned
-
2022
- 2022-06-28 JP JP2022103151A patent/JP2022130561A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019115428A (ru) | 2021-01-11 |
| JP2022130561A (ja) | 2022-09-06 |
| NZ753515A (en) | 2022-02-25 |
| WO2018102536A1 (en) | 2018-06-07 |
| CA3044664A1 (en) | 2018-06-07 |
| CN110662552A (zh) | 2020-01-07 |
| BR112019010943A2 (pt) | 2019-10-01 |
| IL266847A (en) | 2019-07-31 |
| BR112019010943A8 (pt) | 2023-02-07 |
| RU2765410C2 (ru) | 2022-01-28 |
| AU2017368155B2 (en) | 2022-02-24 |
| US20220340653A1 (en) | 2022-10-27 |
| JP7126269B2 (ja) | 2022-08-26 |
| EP3548071A4 (en) | 2020-07-15 |
| MX2019006072A (es) | 2019-08-14 |
| US11136384B2 (en) | 2021-10-05 |
| US11230596B2 (en) | 2022-01-25 |
| EP3548071A1 (en) | 2019-10-09 |
| KR20190088057A (ko) | 2019-07-25 |
| US20190284269A1 (en) | 2019-09-19 |
| IL266847B (en) | 2022-10-01 |
| IL266847B2 (en) | 2023-02-01 |
| KR102461228B1 (ko) | 2022-10-31 |
| JP2020503273A (ja) | 2020-01-30 |
| US20210101971A1 (en) | 2021-04-08 |
| CA3044664C (en) | 2022-11-22 |
| AU2017368155A1 (en) | 2019-05-30 |